Immunize

Menomune

search

Menomune, MPSV4, Quadrivalent Meningococcal Polysaccharide Vaccine

  • Indications
  1. See Menactra (MCV4) which is preferred due to higher immunogenicity
  • Mechanism
  1. Quadrivalent Meningococcal Polysaccharide Vaccine
  2. Covers strains A, C, W-135, and Y (does not contain B serotype)
    1. Covers same strains as Menactra
    2. See Menactra for further explanation
  3. Cost: $100 (similar to Menactra)
  4. Storage: 35 to 46 F (2 to 8 C), Same as Menactra
  • Dose
  • Menomune
  1. Adult: 0.5 ml SC every 3 years
  2. Intramuscular may be preferred over subcutaneous route
    1. Intramuscular Injection reduces adverse effects
      1. Local erythema (11% for IM, 32% for SC)
      2. Headache (3% for IM and 12% for SC)
    2. Intramuscular has same efficacy as subcutaneous route
  • Efficacy
  1. Like Menactra, Menomune has a high seroconversion rate (98%-100%)
  2. However Menomune duration is much shorter
    1. Menomune duration lasts 3 years in school age children and less in infants
  • Precautions
  • Safety
  1. No longer contains Thimerosal
  2. Approved for all ages
  3. Safe in Human Immunodeficiency Virus (HIV)
    1. See Immunization in HIV
  • Adverse effects
  1. Serious adverse events are uncommon (<1.3%)
  2. Headache
  3. Fever (in up to 3% of children)
  4. Local reactions (more common with Menactra)